<DOC>
	<DOCNO>NCT02709720</DOCNO>
	<brief_summary>Phase II clinical trial metronomic oral vinorelbine tri-weekly cisplatin induction therapy subsequent concomitantly radiotherapy ( RT ) patient lung cancer ( NSCLC ) locally advance unresectable</brief_summary>
	<brief_title>Locally Advanced Trial Tri-weekly Metronomic Oral Vinorelbine Cisplatin Induction Therapy Subsequent Concomitance With Radiation Therapy Patients With Unresectable Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Hypothesis : At present , administration concomitant chemotherapy radiation therapy consider treatment choice patient unresectable stage III tumor select clinically . There present systemic consider standard treatment combination radical radiotherapy . Nor establish dose standard radiation therapy , know never less 60Gy57 . Vinorelbine show strong radio-sensitizer in-vitro37 effect . In phase II study , The combination oral vinorelbine cisplatin induction therapy concomitantly radiotherapy ( 66Gy ) provide encouraging efficacy result . Recently vortex scheme cisplatin study oral vinorelbine concomitant maintain radiation second cycle chemotherapy test . It therefore priority segment pathology seek treatment regimen improve effectiveness toxicity . Metronomic chemotherapy start idea administer cytostatic divide dos , extend period without interruption , provide advantage expose patient significant dose chemotherapy without worsen toxicity profile . All make attractive treatment strategy , also maintain radio sensitize effect concomitance .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : Patients histologically confirm recent non small cell lung cancer unresectable stage IIIA IIIB . Perform baseline positron emission tomography ( PETCT ) rule presence distant disease confirm nonNSCLC radical surgical treatment candidate . The positive mediastinal lymph node PETCT must confirm histologically . Mediastinal involvement may consider without histologically observe mass lymph node margin distinguish . At least one measurable lesion computerize tomography ( CT ) . Performance status 01 . Life expectancy &gt; 12 week . Age ≥18 year ≤ 75 year . Right renal function : creatinine ≤ 1.5 mg / dl creatinine clearance &gt; 60 ml / min . Right hematologic function : hemoglobin &gt; 10 g / dl , neutrophil ≥ 1500 / mm3 platelet ≥ 100,000 / mm3 . Right hepatic function : bilirubin ≤ 1.5 time upper limit center , transaminases ≤ 2.5 normal limit . Right lung function without bronchodilator : define forced expiratory volume 1 second ( FEV1 ) &gt; 50 % predict normal volume lung diffuse capacity carbon monoxide ( DLCO ) &gt; 40 % predict normal . The proportion normal lung expose &gt; 20 Gy RT ( V20 ) shall ≤ 35 % . Signature informed consent . Weight loss &gt; 10 % 3 month prior study entry . Intestinal problem ensure proper absorption oral vinorelbine . Pregnant lactating woman . Women childbearing potential negative pregnancy test , men woman condition take contraceptive measure throughout study . symptomatic sensory neuropathy &gt; grade 1 toxicity criterion accord CTCAE v4 . Comorbidities uncontrolled . syndrome superior vena cava . pleural pericardial effusion : consider indicative metastatic disease unless proven otherwise . Those still remain cytologically negative malignancy , exudate also exclude . It may include pleural effusion visible chest radiography small perform diagnostic puncture safely . Known hypersensitivity drug similar study drug structure . Previous treatment anticancer drug , previous surgery thoracic radiotherapy lung cancer reason . History malignancy treat properly within 5 year except carcinoma situ cervix breast skin basal cell carcinoma . Concomitant treatment antineoplastic drug investigational . Patients psychological , family , sociological geographical may hinder compliance study protocol monitoring program . history neurological psychiatric disorder impede properly understand inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Cancer Lung Disease</keyword>
	<keyword>NORA</keyword>
	<keyword>GECP 15/02</keyword>
	<keyword>Metronomic administration</keyword>
</DOC>